Translational Safety for Smarter Development Risk Decisions
ClinDeRisk Advisory supports Biotechs, Pharma, CROs (contract research organization), investors and veterinary stakeholders with scientific, mechanism-based safety de-risking strategies from preclinical stages to clinical development and life-cycle.
What ClinDeRisk does
At the interface of basic science, non-clinical safety, clinical development and pharmacovigilance, ClinDeRisk provides focused strategic advisory to anticipate, characterize and mitigate development risks with a translational safety approach.
Scientific, translational and strategic support for assets in human and veterinary development.
Areas of expertise
Review the asset’s selectivity profile, non-clinical signals and data to build tailored clinical monitoring approaches and define meaningful adverse events of special interest accordingly.
Proactive translational safety
Clinical signal analysis
Move from observed clinical signals to mechanistic understanding, characterization and targeted mitigation strategies.
Development risk management
Build robust risk management perspectives to reinforce the credibility of the asset’s safety profile and benefit/risk balance.
Strategic impact
Better anticipation and sharper safety characterization improves informed development decisions, regulatory dialogue and asset value perception.
Mindful risk-taking
Stronger benefit/risk reasoning for assets in development and investment decisions.
Higher credibility with authorities
Improved probability of success in safety discussions through better-characterized profiles.
Valuation support
Sharper safety understanding reduces uncertainty and strengthens strategic asset positioning.